Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab; Trastuzumab emtansine
Indications Early breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms IMpassion050
Sponsors Chugai Pharmaceutical; Roche

14 Sep 2023 Status changed from active, no longer recruiting to completed.
24 Aug 2023 The study has been completed in Germany , according to European Clinical Trials Database record.
12 May 2023 Planned End Date changed from 24 Aug 2023 to 31 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com